← Eichor
Study identifier: NCT07430046 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Repurposing Mirtazapine in Rett Syndrome

Condition: RETT Syndrome With Proven MECP2 Mutation  ·  Sponsor: University of Trieste

PhasePhase 2
Planned participants54
Who can joinFemale, 5 Years to 40 Years
Healthy volunteersNo

About this study

Rett Syndrome (RTT) is a rare neurodevelopmental disorder caused by an MECP2 gene mutation on the X chromosome, primarily affecting females. It causes progressive motor and cognitive decline, loss of speech, repetitive hand movements, breathing issues, seizures, and sleep problems. Given RTT's association with reduced monoamine levels, antidepressants like mirtazapine (MTZ) may help.Preclinical studies in MeCP2-mutant mice and early adult RTT trials showed that MTZ improved respiratory, motor, and neurological function, sleep, and mood, prompting this pediatric and young adult study. The MirtaRett trial is a multicenter, open-label, single-arm, phase II study enrolling 54 female RTT patients (ages 5-40), divided into groups of 18 (5-10, 11-17, 18-40 years). It aims to evaluate MTZ's safety and efficacy for mood, sleep, and motor symptoms, particularly hand control. Other ares of investigation include autonomic function, behavior, caregiver burden, clinical severity, and neuronal plasticity and metabolic biomarkers. Patients will receive escalating doses of MTZ oral solution: initial low doses (3.75-15 mg/day) for two weeks, followed by optimal doses (7.5-30 mg/day) for six months. Safety, tolerability, and symptoms will be monitored over 10 months (3-month screening, 6-month treatment, 1-month follow-up). The study is conducted at four Italian RTT-specialized hospitals, led by the University of Trieste. Partner sites are in Italy, specifically at the hospitals in Milan, Genov…

This description comes directly from the study's public registry record.

Talk to the study team

Enrico Tongiorgi, PhD  ·  +39 348 73477322  ·  tongi@units.it

Always discuss trial participation with your own doctor first.

Locations (4)

Unità di Neuropsichiatria Infantile, IRCCS, Istituto Giannina Gaslini, GenovaGenova, ItalyRecruiting
UOC di Neuropsichiatria Infantile, Policlinico Universitario "Gaetano Martino" di Messina, University of Messina. MessinaMessina, ItalyRecruiting
Centro Epilessia - Unità Neurologia Pediatrica, ASST Ospedale Santi Carlo Paolo - Dipartimento Scienze della Salute, Università di MilanoMilan, ItalyRecruiting
Unità di Pediatria, Dipartimento della Donna e dei Bambini - Policlinico S. M. alle Scotte. SienaSiena, ItalyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07430046